Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Mini oral session: Supportive and palliative care

433MO - Tofacitinib for the treatment of immune-related adverse events in cancer immunotherapy: A multi-center study

Date

02 Dec 2023

Session

Mini oral session: Supportive and palliative care

Topics

Supportive Care and Symptom Management

Tumour Site

Presenters

Qing Liu

Citation

Annals of Oncology (2023) 34 (suppl_4): S1632-S1645. 10.1016/annonc/annonc1388

Authors

Q. Liu1, M. Liu1, Z. Zou2, J. Lin3, Y. Wang1, N. Zhang4, L. Zhao5, J. Zhou6, H. Zhou7, X. Zhou8, X. Jiao9, Y. Yu1, T. Liu1

Author affiliations

  • 1 Department Of Oncology, Zhongshan Hospital Affiliated to Fudan University, 200032 - Shanghai/CN
  • 2 Department Of Cardiology, Renji Hospital Affiliated to Shanghai Jiaotong University School of Medicine, 200127 - Shanghai/CN
  • 3 Department Of Cardiology, Zhongshan Hospital Affiliated to Fudan University, 200032 - Shanghai/CN
  • 4 Department Of Gastroenterology And Hepatology, Zhongshan Hospital Affiliated to Fudan University, 200032 - Shanghai/CN
  • 5 Department Of Endocrinology, Zhongshan Hospital Affiliated to Fudan University, 200032 - Shanghai/CN
  • 6 Department Of Oncology, Shanghai Construction Group (SCG) Hospital, 200032 - Shanghai/CN
  • 7 Department Of Oncology, Xuhui District Central Hospital of Shanghai, 200032 - Shanghai/CN
  • 8 Department Of Radiation Oncology, Fudan University Shanghai Cancer Center, 200032 - Shanghai/CN
  • 9 Department Of Oncology, Changzheng Hospital, 200072 - Shanghai/CN

Resources

This content is available to ESMO members and event participants.

Abstract 433MO

Background

Treatment strategy against immune-related adverse events (irAEs) induced by immune checkpoint inhibitors (ICIs) frequently requires other immunosuppressive agents. Tofacitinib is a rapidly acting JAK-STAT inhibitor with proven efficacy in multiple autoimmune diseases. We aimed to evaluate the efficacy and safety of tofacitinib in the management of irAEs in cancer patients.

Methods

Cancer patients who received ICIs and treated with tofacitinib for the management of irAEs at 6 institutions were retrospectively included in this study. Demographic and clinical characteristics were obtained from electronic medical records. Longitudinal assessment of cardiac troponin T (cTnT) with clinical assessment was utilized to evaluate the benefit of tofacitinib treatment in patients with ICI myocarditis. Progression-free survival (PFS) and overall survival (OS) were also assessed.

Results

Fifty-three patients were included in this study. Median time from irAE onset to tofacitinib therapy was 17 (range, 2-186) days and median duration of tofacitinib treatment was 48.5 (range, 3-277) days. Enrolled patients were subdivided into 3 groups based on clinical severity and steroid responsiveness including 11 life-threatening cases, 30 steroid-resistant cases and 12 cases with steroid taper failure. Clinical remission rate in each group was 54.5%, 96.7%, and 100%, respectively (p<0.01). Tofacitinib was well-tolerated with 4 patients (7.5%) developing infectious events. From the ICI initiation, the overall median PFS was 5.6 (95% CI, 4.0-14.1) months, and the median OS was 16.1 (95% CI, 7.7-NR) months.

Conclusions

Tofacitinib showed promising clinical efficacy in patients experiencing irAEs, particularly in patients who failed to respond to steroid or experienced failure during steroid tapering. Moreover, and most importantly, tofacitinib exhibited a favorable safety profile in cancer patients developing irAEs in terms of both toxicity and anti-tumor activity. Future prospective studies are warranted.

Clinical trial identification

Editorial acknowledgement

Legal entity responsible for the study

The authors.

Funding

Zhongshan Hospital Affiliated to Fudan University; Chinese Society of Clinical Oncology.

Disclosure

All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.